Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7738346 | 0.70 | — | — | |
| SCHEMBL27732469 | 0.69 | CA5A (0.31) | — | |
| SCHEMBL26101438 | 0.69 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL2580674 | 0.67 | — | — | |
| SCHEMBL2864770 | 0.67 | — | — | |
| SCHEMBL446345 | 0.66 | — | — | |
| SCHEMBL569937 | 0.66 | — | — | |
| SCHEMBL8630016 | 0.65 | — | — | |
| SCHEMBL8063871 | 0.63 | — | — | |
| SCHEMBL11090529 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526102-B1 | Inhibitors of PI3 kinase | FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) | 2017-03-08 | — | — | EP | disclosed |
| US-9073927-B2 | Inhibitors of PI3 kinase | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2015-07-07 | — | — | US | disclosed |
| US-20130131057-A1 | NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO (ES) | 2013-05-23 | — | — | US | disclosed |
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2013-02-28 | — | — | US | disclosed |
| EP-2524918-A1 | Imidazopyrazines derivates as kinase inhibitors | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011141713-A1 | NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011089400-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-28 | — | — | WO | disclosed |
| EP-1169327-B1 | L-ARABINO-DISACCHARIDES OF ANTHRACYCLINES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MENARINI RICERCHE SPA (IT) | 2005-11-30 | — | — | EP | disclosed |
| US-6653289-B1 | Anticancer drugs; reduced side effects | MENARINI RICERCHE S.P.A. (IT) | 2003-11-25 | — | — | US | disclosed |
| EP-1169327-A1 | L-ARABINO-DISACCHARIDES OF ANTHRACYCLINES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Menarini Ricerche S.p.A. (IT) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000053615-A1 | L-ARABINO-DISACCHARIDES OF ANTHRACYCLINES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MENARINI RICERCHE S.P.A. (IT) | 2000-09-14 | — | — | WO | disclosed |
| EP-0861848-A1 | Glycolipid derivatives and use thereof | Chiba Flour Milling Co., Ltd. (JP) | 1998-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, MTOR, PIK3C2A | TSHR 2962/4885TDP1 4086/4885 |
| US-20130131057-A1 | NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS | MTOR, PIK3CA, PIK3C2A | TSHR 4049/4885TDP1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.